Research programme: Huntington's disease therapeutics - CHDI/ENKAM PharmaceuticalsAlternative Names: Dekafin 1; FGF receptor agonists - CHDI/ENKAM; HD programme - CHDI/ENKAM; Huntington's disease programme - CHDI/ENKAM
Latest Information Update: 27 Feb 2008
At a glance
- Originator ENKAM Pharmaceuticals A/S
- Developer CHDI; ENKAM Pharmaceuticals A/S
- Class Peptides
- Mechanism of Action Fibroblast growth factor stimulants
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Preclinical Huntington's disease
Most Recent Events
- 27 Feb 2008 Preclinical development is ongoing